seen from China
seen from T1
seen from Singapore
seen from Malaysia
seen from Ukraine
seen from United Kingdom
seen from United States
seen from United States
seen from United States
seen from Italy
seen from China
seen from United States
seen from Germany
seen from Türkiye
seen from China
seen from United States
seen from Türkiye
seen from Italy
seen from Malaysia
seen from Russia
Rheumatic diseases, often known as musculoskeletal disorders, are characterized by pain and a consequent loss in the range of motion and function in various regions of the musculoskeletal system; in some diseases, inflammation manifests itself as swelling, redness, and warmth in the affected areas.
According to the data, upadacitinib significantly enhanced the number of nr-axSpA patients who met the primary endpoint (45 percent) of ASAS40 at Week 14 as compared to placebo (23 percent ). Secondary endpoints included the Ankylosing Spondylitis Disease Activity Score (ASDAS)
Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drug
Upadacitinib Highlights: EULAR 2022Efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis: a double-blind, randomized, placebo-controlled Phase III trial (Abstract # OP0016)
Abbvie's upadacitinib beat placebo in terms of signs and symptoms, pain, function, disease activity, and MRI-detected spine inflammation at Week 14 of the Phase III SELECT-AXIS 2 clinical trial.
According to the data, upadacitinib significantly enhanced the number of nr-axSpA patients who met the primary endpoint (45 percent) of ASAS40 at Week 14 as compared to placebo (23 percent ). Secondary endpoints included the Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Functional Index (BASFI), and MRI Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac joints, and Ankylosing Spondylitis Quality of Life (ASQoL), as well as low disease activity. During 14 weeks of JAK inhibitor treatment, 48 percent and 46% of patients in the upadacitinib and placebo groups, respectively, had adverse events, with no fatalities or significant adverse cardiovascular events.
KOL Insights
This is the first study to show that the JAK inhibitor upadacitinib could be a therapeutic option in patients with active non-radiographic spondyloarthritis. The findings suggest that upadacitinib, an oral therapy, has the potential to help patients with nr-axSpA take control of their disease by reducing inflammation, relieving pain, and improving function.
Conclusion
The disease activity of 30% of people with SpA cannot be controlled with currently approved drugs, according to the current spondyloarthritis treatment regimen.
JAK inhibitors are the most recent class of synthetic (nonbiologic) disease-modifying antirheumatic medicines (DMARDs) that have been shown to be effective in clinical trials for the treatment of axSpA, and their oral route of administration makes them a more convenient treatment option than other therapies, potentially leading to higher compliance. Rheumatoid arthritis and psoriatic arthritis are two conditions for which the medication is already licensed.
Furthermore, Abbvie has previously demonstrated its leadership in the axSpA market with the approval of its lead candidate Rinvoq (upadacitinib) for the treatment of active ankylosing spondylitis. After 14 weeks of treatment, upadacitinib 15 mg once daily showed significant improvements in the signs and symptoms of nr-axSpA compared to placebo, indicating for the first time the possible use of upadacitinib as a treatment option in patients with nr-axSpA.
For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022
Some of the Latest Abstracts launched in EULAR 2022:
Rheumatic and Musculoskeletal Diseases Highlights
Deucravacitinib: A Ray of Hope after a decade of wait! BMS plans to progress its potential game-changer oral TYK2 inhibitor into late-stage clinical development
Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs
Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial
Diagnostic Imaging Equipment Market
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW.
Sialidosis Market
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Also, take a glance at the Blogs by DelveInsight:
How Metaverse is Set to Transform the Healthcare Dynamics?
Role of Mobile Technology in Hemophilia Management
How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry?
How Cloud Computing is Transforming the Healthcare Industry Dynamics?
The Phase IIa trial showed promising findings in assessing the safety and preliminary efficacy of ABX464 in combination with methotrexate (MTX) in patients with moderate-to-severe active RA who had an unsatisfactory response to MTX or/and anti-TNF treatment.
Bristol Myer Squibb’s deucravacitinib, which is an oral selective, allosteric tyrosine kinase 2 (TYK2) inhibitor has been evaluated for multiple immune-mediated diseases, including psoriasis arthritis, inflammatory bowel diseases, active discoid and subacute cutaneous lupus.
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The BE MOBILE 2 trial, displayed a positive safety and efficacy results in patients who were affected by ankylosing spondylitis and poor response or intolerance to two nonsteroidal anti-inflammatory drugs and prior exposure to no more than one TNF inhibitor.
Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial
EULAR 2022: IL-17A & IL-17F with bimekizumab
Bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy and safety from BE MOBILE 2, a Phase III, multicenter, randomized, placebo-controlled study (Abstract # OP0019)
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The BE MOBILE 2 trial, displayed a positive safety and efficacy results in patients who were affected by ankylosing spondylitis and poor response or intolerance to two nonsteroidal anti-inflammatory drugs and prior exposure to no more than one TNF inhibitor.
In Week-16, the bimekizumab group showed 44.8% ASAS40 response rates, in contrast to 22.5% response rates in the placebo group. In Week-24, the follow-up for ASAS40 response rates were 53.8% for patients who received bimekizumab throughout the study and 56.8% response rates for those who switched to placebo at Week-16. 54.3% of the patients experienced treatment-emergent adverse events (TEAEs), who were treated with bimekizumab at weeks 0-16. Patients with active As who were treated with bimekizumab showed rapid and clinically positive reductions in key signs and symptoms of the disease, with ASDAS <2.1 by week 24. In terms of secondary endpoints, objective signs of inflammation, as described by CRP levels and MRI inflammation of the sacroiliac joints and spine, were notably reduced in bimekiumab-treated patients. Commonly, around 7.7% of the individuals treated with bimekizumab were affected by Nasopharyngitis.
Conclusion
The BE MOBILE 2 Phase III study met all its primary and secondary endpoints. Between the TNFi-navie and TNFi-experienced patients, consistent ASA40 response rates were observed.
In patients with active AS, dual inhibition of IL-17A and IL-17F with bimekizumab resulted in rapid, clinically relevant improvements in efficacy outcomes versus placebo. These results will open up the scope for further exploration of humanized monoclonal IgG1 for AS.
For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022
Some of the Latest Abstracts launched in EULAR 2022:
Deucravacitinib: A Ray of Hope after a decade of wait! BMS plans to progress its potential game-changer oral TYK2 inhibitor into late-stage clinical development
Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs
Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial
Rheumatic and Musculoskeletal Diseases Highlights
Diagnostic Imaging Equipment Market
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW.
Sialidosis Market
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Also, take a glance at the Blogs by DelveInsight:
How Metaverse is Set to Transform the Healthcare Dynamics?
Role of Mobile Technology in Hemophilia Management
How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry?
How Cloud Computing is Transforming the Healthcare Industry Dynamics?
The efficacy and safety findings of upadacitinib (RINVOQ) in patients with nr-axSpA and patients with AS who have not responded to biologic disease-modifying antirheumatic drugs (bDMARDs) are highlighted in the SELECT-AXIS 2 trial.
